US Stock Market IPO: BillionToOne files initial public offering

BillionToOne filed for an initial public offering in the United States on Tuesday. The company’s filing comes at a time when U.S. IPO activity is picking up, reversing a slowdown from earlier in the year, when trade-policy uncertainty curbed momentum.

The Menlo Park, California-based precision diagnostics company will list on the Nasdaq under the “BLLN” ticker symbol.

BillionToOne develops molecular diagnostic tests — including a non-invasive prenatal screen and liquid biopsy — for diseases.

It reported revenue of $125.5 million in the first half of 2025, compared with $69 million in the year-ago period, according to the IPO filing.

Net loss narrowed to $4.2 million in the six months ended June 30, from a loss of $15.2 million in the same period last year.

J.P. Morgan, Wells Fargo and William Blair are among the underwriters for the offering.

FAQs

Q1. What is BillionToOne?
A1. BillionToOne develops molecular diagnostic tests — including a non-invasive prenatal screen and liquid biopsy — for diseases.

Q2. What do we know about BillionToOne?
A2. BillionToOne reported revenue of $125.5 million in the first half of 2025, compared with $69 million in the year-ago period, according to the IPO filing.